Godwin Dogbevia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Godwin Dogbevia has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ann-Marie Heinonen
Max Planck Institute for Medical Research, Jahnstrasse 29, Heidelberg D-69120, Germany
1 shared publication - Hannah Jakobi
Max Planck Institute for Medical Research, Jahnstrasse 29, Heidelberg D-69120, Germany
1 shared publication - Mahbubur Rahman
Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka 1229, Bangladesh
1 shared publication - Markus Schwaninger
Institute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lubeck, Lubeck, Germany
1 shared publication - Rolf Sprengel
Max Planck Institute for Medical Research
1 shared publication - Stefan Wölfl
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 11 March 2014
- Published by Springer Nature in BMC Neuroscience
- Vol. 15 (1) , 38
Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7
Bone morphogenic proteins (BMPs) promote the survival of neurons, suggesting a therapeutic application of BMPs in the treatment of acute and chronic neurodegenerative disorders. However, the application of recombinant BMPs in vivo is limited by their short half-life. To provide a continuous supply for functionally active BMPs, we expressed BMP7, BMP2 and the BMP inhibitor Noggin under the control of rAAV vectors in vivo. For visual control of rAAV-mediated BMP (v-BMP) expression we fused the secreted morphogenic polypeptides and the fluorescent reporter protein Venus via the ‘ribosomal skip’ promoting 2A peptide-bridge.
- 11 March 2014
- Published by Springer Nature in BMC Neuroscience
- Vol. 15 (1) , 38
Open AccessNeuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7
Bone morphogenic proteins (BMPs) promote the survival of neurons, suggesting a therapeutic application of BMPs in the treatment of acute and chronic neurodegenerative disorders. However, the application of recombinant BMPs in vivo is limited by their short half-life. To provide a continuous supply for functionally active BMPs, we expressed BMP7, BMP2 and the BMP inhibitor Noggin under the control of rAAV vectors in vivo. For visual control of rAAV-mediated BMP (v-BMP) expression we fused the secreted morphogenic polypeptides and the fluorescent reporter protein Venus via the ‘ribosomal skip’ promoting 2A peptide-bridge.